13F Holdings
中文EN

ATOS ATOSSA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1488039 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-14.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.9%
ROA-82.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.8%
Debt / equity0.00x
Current ratio5.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.38M$4.90M$4.78M$6.16M$5.37M$5.50M$4.16M$3.40M
SG&A expense$2.52M$3.80M$5.09M$5.28M$3.88M$3.54M$3.26M$3.75M
Operating income-$5.90M-$8.69M-$9.87M-$11.44M-$9.25M-$9.04M-$7.41M-$7.15M
Pretax income-$5.64M-$8.49M-$9.59M-$10.94M-$8.69M-$8.42M-$6.72M-$6.35M
Income tax$0$0$0$0$0$0$0$0
Net income-$5.64M-$8.49M-$9.59M-$10.94M-$8.69M-$8.42M-$6.72M-$6.35M
EBITDA-$5.89M-$8.69M-$9.87M-$11.43M-$9.25M-$9.04M-$7.41M-$7.15M
EPS (basic)-0.56-0.95-1.11—-1.01-0.98-0.78—
EPS (diluted)-0.56-0.95-1.11—-1.01-0.98-0.78—
Weighted avg. shares (diluted)9.99M8.91M8.62M—8.62M8.62M8.62M—
Balance sheet
Cash & equivalents$20.57M$26.09M$31.72M$41.30M$51.84M$57.86M$65.12M$71.08M
Current assets$25.18M$31.01M$36.67M$45.62M$55.68M$62.52M$68.74M$74.46M
Total assets$26.45M$32.28M$37.94M$47.61M$58.01M$64.52M$70.75M$76.44M
Current liabilities$4.71M$5.45M$7.46M$8.26M$8.22M$6.82M$5.42M$4.97M
Total liabilities$4.71M$5.45M$7.46M$8.26M$8.22M$6.82M$5.42M$4.97M
Shareholders' equity$21.74M$26.83M$30.49M$39.35M$49.79M$57.70M$65.32M$71.48M
Shares outstanding9.98M9.98M8.61M8.61M129.17M129.17M129.17M8.61M
Cash flow statement
Operating cash flow-$5.52M-$9.64M-$9.58M-$10.54M-$6.00M-$7.26M-$5.96M-$7.05M
Capital expenditure$0$0$0$7,000$7,000$0$9,000$0
Free cash flow-$5.52M-$9.64M-$9.58M-$10.55M-$6.01M-$7.26M-$5.97M-$7.05M
Investing cash flow$0$0$0-$7,000-$7,000$0-$9,000$0
Financing cash flow$0$4.02M$0$0$0$0$0$3.37M
Depreciation & amortization$4,000$4,000$4,000$4,000$4,000$4,000$4,000$4,000
Stock-based compensation$547,000$815,000$722,000$503,000$784,000$796,000$563,000$774,000

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.